See how Checkpoint Therapeutics, Inc.'s FDA-approved Unloxcyt drug for cSCC is set to disrupt the market with innovative ...

Through its collaboration with Nvidia, Genesis is working to accelerate development of its AI platform, Genesis Exploration ...

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology ... by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

Checkpoint Therapeutics Inc (CKPT) stock saw a decline, ending the day at $3.39 which represents a decrease of $-0.28 or -7.63% from the prior close of $3.67. The stock opened at $4 and touched a low ...

Checkpoint Therapeutics (NASDAQ:CKPT – Free Report) had its price objective hoisted by Lake Street Capital from $4.00 to $7.00 in a research note released on Monday morning,Benzinga reports. Lake ...

The Food and Drug Administration (FDA) has approved Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

L1-blocking antibody is now approved for metastatic or locally advanced cutaneous SCC in adults who are not candidates for curative surgery or curative radiation.

While Spruce Biosciences Inc.’s tildacerfont missed its phase II primary endpoint in classic congenital adrenal hyperplasia (CAH) last March, the U.S. FDA has now approved Crenessity (crinecerfont) ...

Novo Nordisk is investing more than $1 billion in a new production facility in Denmark. Elsewhere, drugs from Neurocrine ...

Lake Street analyst Thomas Flaten raised the firm’s price target on Checkpoint Therapeutics (CKPT) to $7 from $4 and keeps a Buy rating on the ...